Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company MassBiologics
DescriptionHCV-neutralizing mAb against HCV E2
Molecular Target HCV E2
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationHepatitis C virus (HCV)
Indication DetailsPrevent HCV infection of donor tissue in patients with end-stage liver disease (ESLD) who are undergoing liver transplantation due to HCV infection.; Treat and prevent HCV infection
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today